The life science company Acucort reports, as planned, no revenue during the fourth quarter, while the results showed small changes. Operating income was SEK -7 million (-7.6). Net income after tax was SEK -6.8 million (-7.5). Earnings per share amounted to SEK -0.06 (-0.09). Cash and cash equivalents amounted to SEK 27 million.Acucort entered into an important distribution agreement with Glenmark during the quarter, an agreement that initially runs for five years. "Overall, the agreement with Glenmark marks the beginning of a new phase for Acucort. With a substantially expanded market and an agreement with a global pharmaceutical company, we have strengthened our position and laid the foundation for continued international expansion," says Acucort's CEO Jonas Jönmark in the report. Acucort, SEK mQ4-2025Q4-2024Net sales00Operating income-7-7.6Net income-6.8-7.5Earnings per share, SEK-0.06-0.09Cash and cash equivalents27